Victory Capital Management’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Victory Capital Management’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-65	Closed	-$468K	–	2802
2021 Q1	$468K	Buy	65 +1	+2%	+$7.2K	﹤0.01%	2236
2020 Q4	$358K	Buy	64 +4	+7%	+$35.4K	﹤0.01%	2220
2020 Q3	$595K	Sell	60 -19	-24%	-$173K	﹤0.01%	1897
2020 Q2	$727K	Buy	79 +71	+888%	+$651K	﹤0.01%	1865
2020 Q1	$74K	Buy	+8	New	+$79K	﹤0.01%	2404
2019 Q4	–	Sell	-4	Closed	-$20K	–	3120
2019 Q3	$20K	Buy	+4	New	+$24.6K	﹤0.01%	3048

Other funds holding IRLA

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SUT

SC US (TTGP) Menlo Park, California $31.9B AUM 28.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PHAM

Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

Victory Capital Management's IRLA Position: Q2 2021 in Review

Victory Capital Management sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2021, closing a stake of 65 shares — an estimated $468K sold.

Victory Capital Management first reported a position in IRLA in Q3 2019 and held it in 6 quarters. The position peaked at $727K in Q2 2020. 100 funds tracked by Wall St. Rank hold IRLA as of Q2 2021.

Victory Capital Management reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Victory Capital Management sold 65 IRulya Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $468K.
Victory Capital Management first reported a position in IRulya Therapeutics Inc. Common Stock in Q3 2019 and held it in 6 quarters.
Victory Capital Management's IRulya Therapeutics Inc. Common Stock position peaked at $727K in Q2 2020.
100 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2021.

Based on Victory Capital Management's 13F filing for Q2 2021, filed 3 Aug 2021.